biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Midatech's Glioblastoma Drug and xB3 Synergy:

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 15, 2023 6:33pm

75 Views

Post# 35224527

RE:RE:RE:RE:RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:

Denali uses the Tf receptor, poof. Would you like a post about the relative distribution of Tf and LRP-1 receptors in the human brain?

Although you could look up my old post about that just as easily as I can.

Or maybe you can find some new literature on it.

jd

<< Previous

Bullboard Posts

Next >>

Three micro-cap stocks on an upswing worth riding